Jun 18, 2020
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera(TM) MRD Testing
Jun 18, 2020
ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM(TM)) to Clinical Research
May 29, 2020
Data Affirming Biocept's Target Selector(TM) Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
May 26, 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
May 19, 2020
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
May 14, 2020
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector(TM) BRAF Kit for Clients' Use in Their Own Laboratories
May 11, 2020
Singlera Genomics Meets with FDA for Rapid Colon Cancer Assay and Has a Clear Path Forward
May 08, 2020
Liquid Biopsy in Cancer Diagnosis and Treatment
Apr 28, 2020
Biocept Announces CE-IVD Mark and Availability of its Target Selector(TM) EGFR Molecular Assay Kit in Europe
Apr 28, 2020
ArcherDX and UCL Present New Minimal Residual Disease Surveillance Data from their Collaboration at 2020 AACR Virtual Annual Meeting
Apr 20, 2020
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector(TM) Technology Validated for Use in Both Tissue and Blood Samples
Apr 09, 2020
Brazil Patent Granted for Biocept's Target Selector(TM) Oncogene Mutation Enrichment and Detection Platform
Apr 02, 2020
New Study Shows Benefit of Using Signatera(TM) Technology for Personalized Monitoring in Gastrointestinal Cancer
Mar 10, 2020
Sysmex Inostics' Updated SafeSEQ Breast Cancer Panel Advances Novel Clinical Uses of ctDNA Through Quantitative Testing
Mar 09, 2020
/DISREGARD RELEASE: Sysmex Inostics GmbH/
Feb 18, 2020
Volition Unveils Its Epigenetic Toolbox
Jan 07, 2020
Predicine and Merck KGaA, Darmstadt, Germany to Present Data at AACR - Advances in Liquid Biopsy Conference 2020
Jan 06, 2020
Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers
Dec 16, 2019
Sysmex Inostics Announces First Results of Tissue-independent Liquid Biopsy for Early Stage Breast Cancer Mutation Characterization and Monitoring Using Ultra-sensitive SafeSEQ Technology
Nov 05, 2019
The Non-invasive Cancer Diagnostics Market is Projected to Grow at Annualized Rate of Nearly 20%, Between 2019 and 2030, Claims Roots Analysis